Mutations in G protein β subunits promote transformation and kinase inhibitor resistance

Nature Medicine

Volumn 21, Issue 1, 2015, Pages 71-75

  Yoda, Akinori ^a   Adelmant, Guillaume ^a   Tamburini, Jerome ^a   Chapuy, Bjoern ^a   Shindoh, Nobuaki ^a,b   Yoda, Yuka ^a   Weigert, Oliver ^c   Kopp, Nadja ^a   Wu, Shuo Chieh ^a   Kim, Sunhee S ^a   Liu, Huiyun ^a   Tivey, Trevor ^a   Christie, Amanda L ^a   Elpek, Kutlu G ^a,d   Card, Joseph ^a   Gritsman, Kira ^a   Gotlib, Jason ^e   Deininger, Michael W ^f   Makishima, Hideki ^g   Turley, Shannon J ^a   Javidi Sharifi, Nathalie ^h   Maciejewski, Jaroslaw P ^g   Jaiswal, Siddhartha ^i,j   Ebert, Benjamin L ^j,k   Rodig, Scott J ^j   Tyner, Jeffrey W ^h   Marto, Jarrod A ^a   Weinstock, David M ^a,k   Lane, Andrew A ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Jounce Therapeutics   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GNB1 PROTEIN, HUMAN; GNB2 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL TRANSFORMATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPHOMA, B-CELL; METABOLISM; MOUSE; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEINS; HUMANS; JANUS KINASE 2; LYMPHOMA, B-CELL; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84923075128     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3751     Document Type: Article

References (39)

1. O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 13, 412-424 (2013).
2. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
3. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
4. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012).
5. Yoda, A. et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 107, 252-257 (2010).
6. Shindoh, N. et al. Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS ONE 7, e49201 (2012).
7. Lucioni, M. et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 118, 4591-4594 (2011).
8. Menezes, J. et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28, 823-829 (2014).
9. Oldham, W.M. & Hamm, H.E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9, 60-71 (2008).
10. Radhika, V. & Dhanasekaran, N. Transforming G proteins. Oncogene 20, 1607-1614 (2001).
11. Van Raamsdonk, C.D. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602 (2009).
12. Vallar, L., Spada, A. & Giannattasio, G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330, 566-568 (1987).
13. Walter, M.J. et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275-1282 (2013).
14. Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247 (2014).
15. Ford, C.E. et al. Molecular basis for interactions of G protein β subunits with effectors. Science 280, 1271-1274 (1998).
16. Wall, M.A. et al. The structure of the G protein heterotrimer Gia1β12. Cell 83, 1047-1058 (1995).
17. Adelmant, G. et al. DNA ends alter the molecular composition and localization of Ku multicomponent complexes. Mol. Cell Proteomics 11, 411-421 (2012).
18. Willardson, B.M. & Tracy, C.M. Chaperone-mediated assembly of G protein complexes. Subcell. Biochem. 63, 131-153 (2012).
19. Hakak, Y. et al. The role of the GPR91 ligand succinate in hematopoiesis. J. Leukoc. Biol. 85, 837-843 (2009).
20. Gupta, S.K. et al. Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Mol. Cell. Biol. 12, 190-197 (1992).
21. Stephens, L. et al. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein β subunits. Cell 77, 83-93 (1994).
22. Crespo, P., Xu, N., Simonds, W.F. & Gutkind, J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein β subunits. Nature 369, 418-420 (1994).
23. Camps, M. et al. Isozyme-selective stimulation of phospholipase C-β2 by G protein β subunits. Nature 360, 684-686 (1992).
24. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
25. Krause, D.S., Lazarides, K., von Andrian, U.H. & Van Etten, R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12, 1175-1180 (2006).
26. Akagi, T. et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 94, 213-223 (2009).
27. Sherborne, A.L. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 42, 492-494 (2010).
28. Tyner, J.W. et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 73, 285-296 (2013).
29. Johannessen, C.M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142 (2013).
30. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
31. van Bodegom, D. et al. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood 120, 2853-2863 (2012).
32. Ficarro, S.B. et al. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal. Chem. 81, 4566-4575 (2009).
33. Ficarro, S.B. et al. Online nanoflow multidimensional fractionation for high-efficiency phosphopeptide analysis. Mol. Cell Proteomics 10, O111.011064 (2011).
34. Askenazi, M., Parikh, J.R. & Marto, J.A. mzAPI: a new strategy for efficiently sharing mass spectrometry data. Nat. Methods 6, 240-241 (2009).
35. Parikh, J.R. et al. multiplierz: an extensible API based desktop environment for proteomics data analysis. BMC Bioinformatics 10, 364 (2009).
36. Askenazi, M., Marto, J.A. & Linial, M. The complete peptide dictionary - a meta-proteomics resource. Proteomics 10, 4306-4310 (2010).
37. Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013).
38. Weigert, O. et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 209, 259-273 (2012).
39. Elpek, K.G. et al. Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site. PLoS ONE 6, e23921 (2011).